Literature DB >> 17935710

Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats.

Jenny L Wiley1.   

Abstract

Schizophrenia is a serious psychiatric disorder that is most frequently treated with the administration of antipsychotics. Although onset of schizophrenia typically occurs in late adolescence, the majority of preclinical research on the behavioral effects of antipsychotics and their mechanism(s) of action has been conducted on adult male animals. In this study, the acute effects of haloperidol (0.03-0.3 mg/kg, i.p.) and clozapine (1-10 mg/kg, i.p.) on locomotor activity were examined in juvenile [postnatal day 22 (PN22)], adolescent (PN40), and adult (>PN70) rats of both sexes. Subsequently, in order to determine whether tolerance to the activity suppressive effects of these drugs would occur in adolescents, PN40 rats were dosed and assessed for an additional nine days. While all groups exhibited some degree of suppression following acute administration of both drugs, juvenile rats were considerably more sensitive to this effect. With sub-chronic administration during late adolescent development (PN40-PN49), tolerance failed to develop. These results emphasize the importance of age in pharmacological characterization of antipsychotics and suggest that pre-adolescents may have enhanced sensitivity to the motor effects of these drugs. Further, they suggest that, similar to adults, older adolescents may not develop tolerance to the activity suppression induced by these two antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17935710      PMCID: PMC2693188          DOI: 10.1016/j.ejphar.2007.09.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

Review 1.  Comparative postnatal development of dopamine D(1), D(2) and D(4) receptors in rat forebrain.

Authors:  F I Tarazi; R J Baldessarini
Journal:  Int J Dev Neurosci       Date:  2000-02       Impact factor: 2.457

2.  Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice.

Authors:  V M Simón; A Parra; J Miñarro; M C Arenas; C Vinader-Caerols; M A Aguilar
Journal:  Eur Neuropsychopharmacol       Date:  2000-05       Impact factor: 4.600

Review 3.  The adolescent brain and age-related behavioral manifestations.

Authors:  L P Spear
Journal:  Neurosci Biobehav Rev       Date:  2000-06       Impact factor: 8.989

4.  Effects of antipsychotic drugs on operant responding after acute and repeated administration.

Authors:  S A Varvel; R E Vann; L E Wise; S D Philibin; J H Porter
Journal:  Psychopharmacology (Berl)       Date:  2002-01-10       Impact factor: 4.530

5.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 6.  Habituation in rodents: a review of behavior, neurobiology, and genetics.

Authors:  Melanie P Leussis; Valerie J Bolivar
Journal:  Neurosci Biobehav Rev       Date:  2006-06-13       Impact factor: 8.989

7.  Chronic administration of haloperidol during development: later psychopharmacological responses to apomorphine and arecoline.

Authors:  I A Shalaby; L P Spear
Journal:  Pharmacol Biochem Behav       Date:  1980-11       Impact factor: 3.533

8.  Fetal behavior and the dopamine system: activity effects of D1 and D2 receptor manipulations.

Authors:  C A Moody; S R Robinson; L P Spear; W P Smotherman
Journal:  Pharmacol Biochem Behav       Date:  1993-04       Impact factor: 3.533

9.  Cannabinoid pharmacological properties common to other centrally acting drugs.

Authors:  Jenny L Wiley; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

10.  Chronic administration of haloperidol during development: behavioral and psychopharmacological effects.

Authors:  L P Spear; I A Shalaby; J Brick
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  7 in total

1.  Delayed yet persistent effects of daily risperidone on activity in developing rats.

Authors:  Rachel M Stevens; Matthew A Gannon; Molly S Griffith; Mark E Bardgett
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

2.  Early-life risperidone administration alters maternal-offspring interactions and juvenile play fighting.

Authors:  Matthew A Gannon; Clifford J Brown; Rachel M Stevens; Molly S Griffith; Cecile A Marczinski; Mark E Bardgett
Journal:  Pharmacol Biochem Behav       Date:  2015-01-17       Impact factor: 3.533

3.  Adult rats treated with risperidone during development are hyperactive.

Authors:  Mark E Bardgett; Julie M Franks-Henry; Kristin R Colemire; Kathleen R Juneau; Rachel M Stevens; Cecile A Marczinski; Molly S Griffith
Journal:  Exp Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.157

4.  Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model.

Authors:  Jing Qiao; Hong Li; Ming Li
Journal:  Neuropsychopharmacology       Date:  2012-11-07       Impact factor: 7.853

5.  Limited generalizability, pharmacological modulation, and state-dependency of habituation towards pro-social 50-kHz calls in rats.

Authors:  Annuska Berz; Camila Pasquini de Souza; Markus Wöhr; Rainer K W Schwarting
Journal:  iScience       Date:  2021-04-20

6.  Effects of Tianeptine on Adult Rats Following Prenatal Stress.

Authors:  Hwayoung Lee; Hyung-Ki Kim; Jun-Tack Kwon; Young Ock Kim; Jonghoon Seo; Sanghyun Lee; Ik-Hyun Cho; Hak-Jae Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-05-31       Impact factor: 2.582

7.  The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.

Authors:  D Feifel; S Mexal; Gilia Melendez; Philip Y T Liu; Joseph R Goldenberg; Paul D Shilling
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.